The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Pharmacogenomics in oncology care
|
---|---|
Published in |
Frontiers in Genetics, April 2014
|
DOI | 10.3389/fgene.2014.00073 |
Pubmed ID | |
Authors |
Kelly K. Filipski, Leah E. Mechanic, Rochelle Long, Andrew N. Freedman |
Abstract |
Cancer pharmacogenomics have contributed a number of important discoveries to current cancer treatment, changing the paradigm of treatment decisions. Both somatic and germline mutations are utilized to better understand the underlying biology of cancer growth and treatment response. The level of evidence required to fully translate pharmacogenomic discoveries into the clinic has relied heavily on randomized control trials. In this review, the use of observational studies, as well as, the use of adaptive trials and next generation sequencing to develop the required level of evidence for clinical implementation are discussed. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 13% |
United States | 1 | 13% |
Unknown | 6 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 63% |
Scientists | 3 | 38% |
Mendeley readers
The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 2% |
United States | 1 | <1% |
Unknown | 123 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 25 | 20% |
Student > Master | 15 | 12% |
Researcher | 14 | 11% |
Student > Ph. D. Student | 14 | 11% |
Other | 7 | 6% |
Other | 21 | 17% |
Unknown | 30 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 26 | 21% |
Medicine and Dentistry | 22 | 17% |
Biochemistry, Genetics and Molecular Biology | 18 | 14% |
Agricultural and Biological Sciences | 11 | 9% |
Nursing and Health Professions | 3 | 2% |
Other | 11 | 9% |
Unknown | 35 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2022.
All research outputs
#5,744,105
of 23,577,654 outputs
Outputs from Frontiers in Genetics
#1,637
of 12,604 outputs
Outputs of similar age
#53,261
of 229,540 outputs
Outputs of similar age from Frontiers in Genetics
#25
of 94 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,604 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,540 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.